Literature DB >> 10051256

Type III and type I procollagen markers in fibrosing alveolitis.

L Lammi1, L Ryhänen, E Lakari, J Risteli, P Pääkkö, K Kahlos, S Lähde, V Kinnula.   

Abstract

Deposition of types I and III collagen is a typical feature in the development of pulmonary fibrosis. We assessed the propeptides of these procollagens as prognostic markers in 18 patients with fibrosing alveolitis. We analyzed the amino-terminal propeptide of type III procollagen (PIIINP) and the carboxy-terminal propeptide of type I procollagen (PICP) from samples of bronchoalveolar lavage fluid (BALF) and serum, and also estimated their concentrations in epithelial lining fluid (ELF) by the urea method. The level of PIIINP in serum (p < 0.05), BALF (p < 0.05), and ELF (p < 0.05), and the levels of PICP in BALF (p < 0.001) and ELF (p < 0.001) but not in serum, were significantly increased in the patients with fibrosing alveolitis as compared with 17 controls who had been investigated for minor respiratory symptoms. In the BALF and ELF of patients with fibrosing alveolitis, PICP but not PIIINP had significant negative correlations with the specific diffusion coefficient for carbon monoxide (DLCO/ VA). The amino-terminal propeptide of type III procollagen and the carboxy-terminal propeptide of type I procollagen in BALF correlated significantly with one another. During the follow-up period of 6 yr, seven of the 18 patients with fibrosing alveolitis died of the disease, 3 others died of malignancy, and one patient died from an unknown cause. DLCO (p < 0.05) differed significantly between the surviving patients and those who died of fibrosing alveolitis, and detectable PIIINP in BALF predicted death from fibrosing alveolitis (p = 0.05). In conclusion, these results show that PIIINP in BALF, ELF, and serum, and PICP in BALF and ELF, are increased in patients with fibrosing alveolitis. A high level of PICP in BALF, and especially in ELF, suggests a chronic process and increased synthesis of type I collagen in the lungs, whereas PIIINP in BALF and ELF suggests active disease and a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051256     DOI: 10.1164/ajrccm.159.3.9805060

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  12 in total

Review 1.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Activated alveolar epithelial cells initiate fibrosis through secretion of mesenchymal proteins.

Authors:  Jibing Yang; Sarah E Wheeler; Miranda Velikoff; Kathryn R Kleaveland; Michael J LaFemina; James A Frank; Harold A Chapman; Paul J Christensen; Kevin K Kim
Journal:  Am J Pathol       Date:  2013-09-05       Impact factor: 4.307

3.  Serum concentration of procollagen type III amino-terminal peptide is increased in patients with successfully repaired coarctation of the aorta with left ventricular hypertrophy.

Authors:  Hirokuni Yamazawa; Tomoaki Murakami; Atsuhito Takeda; Kouta Takei; Takuo Furukawa; Hiromichi Nakajima
Journal:  Pediatr Cardiol       Date:  2014-10-14       Impact factor: 1.655

4.  Localization of precursor proteins and mRNA of type I and III collagens in usual interstitial pneumonia and sarcoidosis.

Authors:  Riitta Kaarteenaho-Wiik; Lauri Lammi; Essi Lakari; Vuokko L Kinnula; Juha Risteli; Lasse Ryhänen; Paavo Pääkkö
Journal:  J Mol Histol       Date:  2006-03-07       Impact factor: 2.611

5.  Tuberculosis: time for a new perspective?

Authors:  Paul T Elkington
Journal:  J Infect       Date:  2013-02-12       Impact factor: 6.072

6.  Variability in the precursor proteins of collagen I and III in different stages of COPD.

Authors:  Terttu Harju; Vuokko L Kinnula; Paavo Pääkkö; Kaisa Salmenkivi; Juha Risteli; Riitta Kaarteenaho
Journal:  Respir Res       Date:  2010-11-30

7.  Overexpression of PTEN suppresses lipopolysaccharide-induced lung fibroblast proliferation, differentiation and collagen secretion through inhibition of the PI3-K-Akt-GSK3beta pathway.

Authors:  Zhengyu He; Yuxiao Deng; Wen Li; Yongming Chen; Shunpeng Xing; Xianyuan Zhao; Jia Ding; Yuan Gao; Xiangrui Wang
Journal:  Cell Biosci       Date:  2014-01-06       Impact factor: 7.133

8.  The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.

Authors:  Matthew Hammond; Allan B Clark; Anthony P Cahn; Edwin R Chilvers; William Duncan Fraser; David M Livermore; Toby M Maher; Helen Parfrey; Ann Marie Swart; Susan Stirling; David Thickett; Moira Whyte; Andrew Wilson
Journal:  Trials       Date:  2018-02-05       Impact factor: 2.279

9.  Inhibiting toll-like receptor 4 signaling ameliorates pulmonary fibrosis during acute lung injury induced by lipopolysaccharide: an experimental study.

Authors:  ZhengYu He; YeSen Zhu; Hong Jiang
Journal:  Respir Res       Date:  2009-12-18

10.  Procollagen III N-terminal propeptide and desmosine are released by matrix destruction in pulmonary tuberculosis.

Authors:  Jo Seddon; Victoria Kasprowicz; Naomi F Walker; Ho Ming Yuen; Henry Sunpath; Liku Tezera; Graeme Meintjes; Robert J Wilkinson; William R Bishai; Jon S Friedland; Paul T Elkington
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.